ArticleAmerican journal of therapeutics2021
Tocilizumab Induces Rapid, Sustained Improvement of Inflammatory Markers in COVID-19, With Clinical Improvement in Most Patients.
Scott J Morin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.